602 related articles for article (PubMed ID: 33142986)
1. Radioprotection and Radiomitigation: From the Bench to Clinical Practice.
Obrador E; Salvador R; Villaescusa JI; Soriano JM; Estrela JM; Montoro A
Biomedicines; 2020 Oct; 8(11):. PubMed ID: 33142986
[TBL] [Abstract][Full Text] [Related]
2. Radioprotectors - the evergreen topic.
Kuntić VS; Stanković MB; Vujić ZB; Brborić JS; Uskoković-Marković SM
Chem Biodivers; 2013 Oct; 10(10):1791-803. PubMed ID: 24130023
[TBL] [Abstract][Full Text] [Related]
3. Biologics as countermeasures for acute radiation syndrome: where are we now?
Singh VK; Romaine PL; Newman VL
Expert Opin Biol Ther; 2015 Apr; 15(4):465-71. PubMed ID: 25416452
[TBL] [Abstract][Full Text] [Related]
4. An update on sargramostim for treatment of acute radiation syndrome.
Singh VK; Seed TM
Drugs Today (Barc); 2018 Nov; 54(11):679-693. PubMed ID: 30539167
[TBL] [Abstract][Full Text] [Related]
5. Medical countermeasures for unwanted CBRN exposures: part II radiological and nuclear threats with review of recent countermeasure patents.
Singh VK; Romaine PL; Newman VL; Seed TM
Expert Opin Ther Pat; 2016 Dec; 26(12):1399-1408. PubMed ID: 27610458
[TBL] [Abstract][Full Text] [Related]
6. γ-Tocotrienol as a Promising Countermeasure for Acute Radiation Syndrome: Current Status.
Singh VK; Hauer-Jensen M
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27153057
[TBL] [Abstract][Full Text] [Related]
7. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
Heaney ML; Toy EL; Vekeman F; Laliberté F; Dority BL; Perlman D; Barghout V; Duh MS
Cancer; 2009 Oct; 115(20):4839-48. PubMed ID: 19637341
[TBL] [Abstract][Full Text] [Related]
8. Appraisal of biochemical classes of radioprotectors: evidence, current status and guidelines for future development.
Mishra K; Alsbeih G
3 Biotech; 2017 Oct; 7(5):292. PubMed ID: 28868219
[TBL] [Abstract][Full Text] [Related]
9. Colony-stimulating factors for the treatment of the hematopoietic component of the acute radiation syndrome (H-ARS): a review.
Singh VK; Newman VL; Seed TM
Cytokine; 2015 Jan; 71(1):22-37. PubMed ID: 25215458
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of amifostine for the acute radiation syndrome.
Singh VK; Seed TM
Expert Opin Drug Saf; 2019 Nov; 18(11):1077-1090. PubMed ID: 31526195
[No Abstract] [Full Text] [Related]
11. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status.
Singh VK; Garcia M; Seed TM
Int J Radiat Biol; 2017 Sep; 93(9):870-884. PubMed ID: 28657406
[TBL] [Abstract][Full Text] [Related]
12. Sargramostim in acute radiation syndrome.
Lazarus HM; McManus J; Gale RP
Expert Opin Biol Ther; 2022 Nov; 22(11):1345-1352. PubMed ID: 36325797
[TBL] [Abstract][Full Text] [Related]
13. Synthetic and Natural Radioprotective Agents: Recent Status and their Underlying Mechanism of Action.
Mishra J; Poonia N; Lather V; Kumar Nishad D; Pandita D
Curr Pharm Biotechnol; 2024 May; ():. PubMed ID: 38818911
[TBL] [Abstract][Full Text] [Related]
14. Radiation Protection and Mitigation by Natural Antioxidants and Flavonoids: Implications to Radiotherapy and Radiation Disasters.
Yahyapour R; Shabeeb D; Cheki M; Musa AE; Farhood B; Rezaeyan A; Amini P; Fallah H; Najafi M
Curr Mol Pharmacol; 2018; 11(4):285-304. PubMed ID: 29921213
[TBL] [Abstract][Full Text] [Related]
15. CBLB613: a TLR 2/6 agonist, natural lipopeptide of Mycoplasma arginini , as a novel radiation countermeasure.
Singh VK; Ducey EJ; Fatanmi OO; Singh PK; Brown DS; Purmal A; Shakhova VV; Gudkov AV; Feinstein E; Shakhov A
Radiat Res; 2012 May; 177(5):628-42. PubMed ID: 22175300
[TBL] [Abstract][Full Text] [Related]
16. A wearable gamma radiation-responsive granulocyte colony-stimulating factor microneedle system protecting against ionizing radiation-induced injury.
Yu X; Zhu L; Liang X; Yuan B; Li M; Hu S; Ding P; Du L; Guo J; Jin Y
Acta Biomater; 2022 Jul; 146():197-210. PubMed ID: 35487423
[TBL] [Abstract][Full Text] [Related]
17. Combining Pharmacological Countermeasures to Attenuate the Acute Radiation Syndrome-A Concise Review.
Hofer M; Hoferová Z; Depeš D; Falk M
Molecules; 2017 May; 22(5):. PubMed ID: 28534834
[TBL] [Abstract][Full Text] [Related]
18. Appraisal of mechanisms of radioprotection and therapeutic approaches of radiation countermeasures.
Mishra KN; Moftah BA; Alsbeih GA
Biomed Pharmacother; 2018 Oct; 106():610-617. PubMed ID: 29990850
[TBL] [Abstract][Full Text] [Related]
19. Romiplostim (Nplate
Bunin DI; Bakke J; Green CE; Javitz HS; Fielden M; Chang PY
Int J Radiat Biol; 2020 Jan; 96(1):145-154. PubMed ID: 31021662
[No Abstract] [Full Text] [Related]
20. Trends in pharmacological stimulation of regeneration of ionizing radiation-damaged mammalian organism.
Hofer M
Cas Lek Cesk; 2020; 159(7-8):275-280. PubMed ID: 33445933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
